Unleashing the Power of NR4A1 Degradation as a Novel Strategy for Cancer Immunotherapy
L. Wang, Y. Xiao, Y. Luo, R. P. Master, J. Mo, M.-C. Kim, Y. Liu, U. M. Patel, X. Li, D. Shaffer, K. R. Guertin, E. Moser, K. Smalley, D. Zhou, G. Zheng, W. Zhang
This paper develops a PROTAC molecule (NR-V04) that degrades NR4A1, leading to tumor inhibition and immune modulation in melanoma.
bioRxiv · Aug 9, 2023 · PreprintCancer Biology